Sotetsuflavone

Synonyms: 苏铁双黄酮
Sotetsuflavone 是一种可从 Cycas revolute 中分离得到的黄酮类化合物,可抑制 PI3K、Akt、mTOR、JNK 和 p38 MAPK 的磷酸化,调控 Cyclin D1、CDK4、Bcl-2、Bax、活化型 caspases 3/9、MMP-9、TGF-β、STAT3 及 β-catenin 的表达,并可诱导 G0/G1 期细胞周期阻滞、细胞凋亡 (apoptosis)、自噬 (autophagy) 及细胞内 ROS 水平升高,从而抑制癌细胞增殖和小鼠肿瘤生长,可用于非小细胞肺癌和克罗恩病的相关研究。
产品编号: MS-R80285 CAS No.: 2608-21-1 分子式: C31H20O10 分子量: 552.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Sotetsuflavone 是一种可从 Cycas revolute 中分离得到的黄酮类化合物,可抑制 PI3K、Akt、mTOR、JNK 和 p38 MAPK 的磷酸化,调控 Cyclin D1、CDK4、Bcl-2、Bax、活化型 caspases 3/9、MMP-9、TGF-β、STAT3 及 β-catenin 的表达,并可诱导 G0/G1 期细胞周期阻滞、细胞凋亡 (apoptosis)、自噬 (autophagy) 及细胞内 ROS 水平升高,从而抑制癌细胞增殖和小鼠肿瘤生长,可用于非小细胞肺癌和克罗恩病的相关研究。

生物实验数据

生物活性 Sotetsuflavone is a flavonoid isolated from Cycas revolute that inhibits the phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK, regulates the expression of Cyclin D1, CDK4, Bcl-2, Bax, activated caspases 3/9, MMP-9, TGF-β, STAT3, and β-catenin, and induces G0/G1 cell cycle arrest, apoptosis, autophagy, and elevated intracellular ROS levels, thereby inhibiting cancer cell proliferation and mouse tumor growth, and it can be used for research related to non-small cell lung cancer and Crohn's disease.
体外研究
(In Vitro)

Sotetsuflavone (64-128 μmol/L; 24 h) 抑制 A549 和 H1650 非小细胞肺癌细胞中的 PI3K/Akt/mTOR 信号通路。
Sotetsuflavone (5-200 μmol/L; 24 h) 可呈剂量依赖性抑制 H1650 非小细胞肺癌细胞的活力,IC50 为 67.54 μmol/L。
Sotetsuflavone (64-128 μmol/L; 14 days) 可显著抑制 A549 和 H1650 非小细胞肺癌细胞的集落形成。
Sotetsuflavone (64-128 μmol/L; 24 h) 可显著抑制 H1650 细胞的迁移能力。
Sotetsuflavone (64-128 μmol/L) 可显著抑制 H1650 非小细胞肺癌细胞的侵袭。
Sotetsuflavone (64-128 μmol/L; 24 h) 可显著诱导 A549 和 H1650 非小细胞肺癌细胞发生凋亡。
Sotetsuflavone (64-128 μmol/L) 可调控 H1650 非小细胞肺癌细胞中凋亡及细胞周期相关蛋白的表达,降低 cyclin D1、CDK4 和 Bcl-2 的表达水平,同时上调 Bax、剪切型 cleaved-caspase 3/9 和细胞色素 C 的表达水平。
Sotetsuflavone (64-128 μmol/L; 24 h) 可在 H1650 非小细胞肺癌细胞发生 G0/G1 期细胞周期阻滞。
Sotetsuflavone (64-128 μmol/L; 24 h) 可在 A549 非小细胞肺癌细胞发生自噬。
Sotetsuflavone (64-128 μmol/L; 24 h) 可促进 A549 非小细胞肺癌细胞中自噬体的形成。
Sotetsuflavone (64-128 μmol/L; 24 h) 可促进 A549 非小细胞肺癌细胞中酸性囊泡细胞器的形成,提示自噬水平增强。
Sotetsuflavone (5-200 μmol/L; 12-48 h) 可呈时间和剂量依赖性抑制 A549 细胞增殖。
Sotetsuflavone (64-128 μmol/L; 24 h) 可剂量依赖性地升高 A549 细胞内的 ROS 水平。
Sotetsuflavone (64-128 μmol/L; 24 h) 可剂量依赖性降低 A549 细胞的线粒体膜电位。
Sotetsuflavone (64-128 μmol/L; 24 h) 可呈剂量依赖性调控人非小细胞肺癌 A549 细胞中的上皮-间质转化标记蛋白,可上调 E-cadherin 表达并下调 Snail、HIF-1α、MMP-9/13、VEGF、TNF-α、NF-κB 表达。
Sotetsuflavone (64-128 μmol/L; 24 h) 可呈剂量依赖性抑制人非小细胞肺癌 A549 细胞中 PI3K 和 AKT 的表达,从而抑制 PI3K/AKT 通路的激活。
Sotetsuflavone (64-128 μmol/L; 24 h) 可浓度依赖性地下调人非小细胞肺癌 A549 细胞中 STAT3、β-catenin 和 TGF-β 的 mRNA 表达,并上调 ZO-1 的 mRNA 表达。
Sotetsuflavone (25-100 μM; 24 h) 可剂量依赖性地抑制 LPS 联合 IFN-γ 诱导的 RAW264.7 巨噬细胞中 JNK 和 p38 的磷酸化。
Sotetsuflavone (50 μM; 12 h 预处理) 可抑制 LPS 联合 IFN-γ 诱导的 RAW264.7 巨噬细胞中 M1 巨噬细胞标记基因 iNOS 和 IRF-5 的上调,该效应通过抑制 p38 信号通路介导。
Sotetsuflavone (50 μM; 12 h 预处理) 可通过抑制 p38 和 JNK 信号通路,保护小鼠结肠类器官免受 M1 巨噬细胞诱导的损伤,包括类器官体积减小、出芽受损及通透性增加。

Western Blot Analysis

Cell Line: A549 and H1650 non-small cell lung cancer cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Reduced the phosphorylation levels of PI3K, Akt, mTOR, Raptor, and p70S6K in A549 cells.
Significantly increased LC3-II conversion and reduced P62 expression in both A549 and H1650 cells when co-treated with 20 μM LY294002 (MS-X98356).

Cell Viability Assay

Cell Line: H1650 non-small cell lung cancer cells
Concentration: 5; 10; 20; 40; 80; 100; 120; 160; 200 μmol/L
Incubation Time: 24 h
Result: Inhibited H1650 cell growth in a dose- and time-dependent manner.
Exhibited an IC50 value of 67.54 μmol/L.

Cell Proliferation Assay

Cell Line: A549 and H1650 non-small cell lung cancer cells
Concentration: 64; 128 μmol/L
Incubation Time: 14 days
Result: Reduced A549 cell colony numbers to ~35% and ~15% of control at 64 and 128 μmol/L, respectively.
Reduced H1650 cell colony numbers to ~30% and ~10% of control at 64 and 128 μmol/L, respectively.

Cell Migration Assay

Cell Line: H1650 non-small cell lung cancer cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Reduced H1650 cell migration to ~55% and ~35% of control at 64 and 128 μmol/L, respectively.

Cell Cycle Analysis

Cell Line: H1650 non-small cell lung cancer cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Increased the proportion of H1650 cells in the G0/G1 phase and decreased the proportion in the G2/M phase compared to control.

Cell Proliferation Assay

Cell Line: human non-small cell lung cancer A549 cells
Concentration: 5; 10; 20; 40; 80; 100; 120; 160; 200 μmol/L
Incubation Time: 12; 24; 48 h
Result: Inhibited A549 cell proliferation in a time- and dose-dependent manner.
Reduced cell viability significantly at concentrations ≥80 μmol/L across all incubation times.
Showed no significant difference in inhibitory effect between 12 h, 24 h, and 48 h at concentrations >80 μmol/L.
Exhibited IC50 values of 87 μmol/L for 12 h incubation, 71 μmol/L for 24 h incubation, and 63 μmol/L for 48 h incubation.

Apoptosis Analysis

Cell Line: human non-small cell lung cancer A549 cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Induced apoptosis in A549 cells in a dose-dependent manner.
Increased the apoptosis ratio from a low control level to ~10% at 64 μmol/L and ~32% at 128 μmol/L.
Increased green (Annexin V-FITC) and red (PI) staining with higher sotetsuflavone concentrations.\nIncreased the number of cells with condensed, fragmented bright blue nuclei (apoptotic cells) in a dose-dependent manner.

Western Blot Analysis

Cell Line: human non-small cell lung cancer A549 cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Downregulated cell cycle-related proteins Cyclin D1 and CDK4 in a dose-dependent manner.
Upregulated pro-apoptotic proteins Bax, cleaved caspase-3, cleaved caspase-9, and cytochrome C in a dose-dependent manner.
Downregulated anti-apoptotic protein Bcl-2 and death receptor pathway protein cleaved caspase-8 in a dose-dependent manner.
Increased the Bax/Bcl-2 ratio.

Western Blot Analysis

Cell Line: human non-small-cell lung cancer A549 cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Upregulated E-cadherin protein expression in a dose-dependent manner compared to the control group.
Downregulated Snail protein expression in a dose-dependent manner compared to the control group.

Real Time qPCR

Cell Line: human non-small-cell lung cancer A549 cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Downregulated mRNA expression of Snail in a dose-dependent manner compared to the control group.
Downregulated mRNA expression of Vimentin in a dose-dependent manner compared to the control group.
Downregulated mRNA expression of N-cadherin in a dose-dependent manner compared to the control group.

Immunofluorescence

Cell Line: human non-small cell lung cancer A549 cells
Concentration: 64; 128 μmol/L
Incubation Time: 24 h
Result: Significantly increases endostatin fluorescence intensity and significantly decreases TGF-β fluorescence intensity compared to control at 64 μmol/L.
Produces a further significant increase in endostatin fluorescence intensity and further significant decrease in TGF-β fluorescence intensity compared to control at 128 μmol/L, with effects showing a concentration-dependent trend.
Localizes endostatin primarily to the A549 cell membrane, while TGF-β is localized primarily to the cytoplasm.
...(内容过长已截断)
体内研究
(In Vivo)

Sotetsuflavone (20-40 mg/kg;腹腔注射;每 4 天 1 次;持续 28 天) 可抑制 BALB/C 裸鼠体内非小细胞肺癌异种移植物的生长。
Sotetsuflavone (40 mg/kg;腹腔注射;隔日一次;持续 4 周) 可改善 IL-10-/-小鼠的自发性克罗恩病样结肠炎。

Animal Model: BALB/C mice (male, 4 weeks old) subcutaneously inoculated with A549 cells
Dosage: 20; 40 mg/kg
Administration: i.p.; every 4 days; 28 days
Result: Significantly reduced tumor volume and mean tumor weight relative to control.
Resulted in lower mean tumor weight at 40 mg/kg dose than at 20 mg/kg dose.
Increased apoptotic cells in tumor tissues, with more apoptosis observed in the 40 mg/kg group.
Increased LC3 expression and decreased P62 expression in tumor tissues.
Maintained stable mouse body weight throughout the study.
Showed no serious morphological changes in lung, intestine, or liver tissues.
Animal Model: IL-10-/- mice (15-week-old male) with colitis
Dosage: 40 mg/kg
Administration: i.p.; every other day; 4 weeks
Result: Significantly reduced disease activity index (DAI) scores starting 2 weeks post-treatment.
Increased net weight change relative to untreated IL-10-/- mice.
Attenuated colon shortening.
Reduced macroscopic colonic mucosal injury scores to 3.63 and colonic inflammatory scores to 2.
Lowered serum intestinal fatty acid binding protein (I-FABP) levels and blood FITC-dextran levels.
Increased transepithelial electric resistance (TEER) of colon tissues.
Reduced bacterial translocation rate to mesentery lymph nodes (MLNs) from 37.25% to 12.5% and to liver from 31.25% to 6.25%.
Decreased the percentage of iNOS+/F4/80+ M1 macrophages from 7.69% to 3.89%, increased the percentage of CD206+/F4/80+ M2 macrophages from 8.91% to 13.14%, and reduced the M1/M2 ratio.
Decreased protein and mRNA levels of proinflammatory cytokines TNF-α, IL-6, IFN-γ, and IL-1β.
Inhibited phosphorylation of JNK and p38 in intestinal epithelial macrophages.
性状 固体
颜色 Light brown to brown

化学信息

分子量 552.48
分子式 C31H20O10
CAS No. 2608-21-1
别名 苏铁双黄酮

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

苏铁双黄酮 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础